辅酶Ⅰ联合洛伐他汀对冠心病患者心功能及血清炎症因子水平的影响  

Effect of coenzyme Ⅰ combined with lovastatin on cardiac function and levels of serum inflammatory factors in patients with coronary heart disease

作　　者：曹婷婷 杨麦广 CAO Tingting;YANG Maiguang(Department of Cardiology,Neihuang County People's Hospital,Anyang Henan 456300,China)

机构地区：[1]内黄县人民医院心内科,河南安阳456300

出　　处：《实用心电学杂志》2024年第6期625-628,636,共5页Journal of Practical Electrocardiology

摘　　要：目的 探究辅酶Ⅰ联合洛伐他汀对冠心病患者心功能及血清炎症因子水平的影响。方法 回顾性分析120例冠心病患者的临床资料,其中60例采用洛伐他汀治疗(洛伐他汀组),另外60例采用洛伐他汀+注射用辅酶Ⅰ治疗(联合用药组)。比较两组治疗前后的心功能(室壁运动评分指数、左心室射血分数)、血清炎症因子(超敏C反应蛋白、核因子-κB、肿瘤坏死因子-α、白介素-1)及血脂(低密度脂蛋白胆固醇、甘油三酯、高密度脂蛋白胆固醇、总胆固醇)水平,以及临床疗效、不良反应发生率。结果 联合用药组临床总有效率明显高于洛伐他汀组(90.00%vs.75.00%;χ^(2)=4.675,P<0.05),心功能、血清炎症因子及血脂水平改善程度亦明显优于洛伐他汀组(均P<0.05);两组不良反应发生率间的差异无统计学意义(16.67%vs.6.67%;χ^(2)=2.911,P>0.05)。结论 注射用辅酶Ⅰ联合洛伐他汀治疗冠心病,对心功能的改善、血脂水平的调节作用明显提高,疗效优于单用洛伐他汀,且安全性较高。Objective To explore the effect of coenzyme Ⅰ combined with lovastatin on cardiac function and the levels of serum inflammatory factors in patients with coronary heart disease(CHD).Methods Retrospective analysis was performed on the clinical data of 120 CHD patients.Among them,60 cases had been treated with lovastatin as the lovastatin group(lovastatin group),while another 60 cases were given lovastatin + coenzyme Ⅰ for injection as the combined medication group.The clinical efficacy and adverse reaction incidences between the two groups were compared,as well as the cardiac function(wall motion score index and LVEF),and serum inflammatory factors(high-sensitivity C-reactive protein,nuclear factor Kappa B),(tumor necrosis factor-α and interleukin-1) and blood lipid(LDL-C,triglyceride,HDL-C and total cholesterol) levels before and after treatment.Results The total clinical effective rate of the combined medication group was statistically higher than that of the lovastatin group(90.00% vs.75.00%;χ~2=4.675,P<0.05).The improvement of cardiac function,and serum inflammatory factors and blood lipid levels in the combined medication group was also better than that in the lovastatin group(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(16.67% vs.6.67%;χ~2=2.911,P>0.05).Conclusion In the treatment of CHD,the combination of coenzyme Ⅰ for injection and lovastatin significantly improves cardiac function and the regulation of blood lipid level.Its efficacy is better than that of lovastatin alone with high safety.

关 键 词：辅酶Ⅰ 洛伐他汀 冠心病 心功能 血清炎症因子 

分 类 号：R541.4[医药卫生—心血管疾病]